HOME › Research Insight › Emerging nations are expected to be the key focus areas due to high adoption of INAAT in infection detection and point-of-care testing

Emerging nations are expected to be the key focus areas due to high adoption of INAAT in infection detection and point-of-care testing

The isothermal nucleic acid amplification technology (INAAT) market is estimated to reach $1,651 million by 2018 at a CAGR of 13.5% during the forecast period. The INAAT is an alternative method of polymerase chain reaction (PCR) for amplifying DNA and RNA strands during molecular testing. Though PCR technology dominates the nucleic acid amplification technology market currently, INAAT is expected to witness a significant adoption in the coming years as it demonstrates advancements in pathogen detection.

Reagent segment accounts for the largest share of 70% of the global INAAT market in 2013; the segment is also expected to grow at a double digit growth due to increasing consumption of reagents for reliable, specific and faster detection of chronic diseases and genetic disorders. On the other hand, novel technologies such as Loop-Mediated Isothermal Amplification (LAMP), Nucleic Acid Sequence Based Amplification (NASBA) and Helicase Dependent Amplification (HDA) are expected to witness significant growth in the global INAAT instrument market as it provides less expensive and timely diagnosis, as compared to conventional methods using PCR technology.

Infectious disease was found to be the highest revenue generating segment of the global INAAT market in 2013; it accounted for the largest share of 57.2% of the global INAAT market in 2013 and is expected to grow at 14.4% CAGR during the forecast period. The significant growth of infectious disease application market is attributed to high incidence of various infectious diseases such as HIV and hepatitis A & B, and increasing adoption of INAAT in infection detection globally. In addition to infectious disease application, the study also found an emerging scope of isothermal technology in blood screening application to ensure the quality of donated blood through its early prognosis of pathogen; whereas, adoption of INAAT is still limited in research application globally. Increasing adoption in cancer research, whole genome amplification, mutation, SNP detection and expression analysis is expected to drive the INAAT research application market.

Hospital segment holds the maximum share of the global INAAT end-user market in 2013; whereas, reference laboratories is expected to grow at a higher CAGR of 14.9% during the forecast period. Increasing volume of reference laboratories globally and rising importance of isothermal technology in different complex molecular testing are identified as the prime factors for market growth.

North America commanded the largest market share of about 44% in 2013; it is poised to grow at a CAGR of 13.3% during the forecast period. Asian INAAT market is expected to witness the highest CAGR due to increasing prevalence of infectious diseases and governments’ initiative behind the rapid adoption of novel technologies in molecular testing. Leading players in the global INAAT market are also expected to capitalize on the unmet needs in emerging nations such as India, China, South Africa, Singapore, and Middle East in the coming years.